Baseline patient and disease characteristics
| . | N = 39 . | |
|---|---|---|
| Sex, n (%) | ||
| Male | 28 | 71.8% |
| Female | 11 | 28.2% |
| Race, n (%) | ||
| White | 26 | 66.7% |
| Black | 12 | 30.8% |
| Asian | 1 | 2.6% |
| Ethnicity, n (%) | ||
| Hispanic/Latino | 1 | 2.6% |
| Non-Hispanic | 37 | 94.9% |
| Unknown | 1 | 2.6% |
| Age at on study, median (range), y | 62 | 34-78 |
| M-protein isotype, n (%) | ||
| IgGκ | 20 | 51.3% |
| IgGλ | 10 | 25.6% |
| IgAκ | 2 | 5.1% |
| IgAλ | 2 | 5.1% |
| κ light chain | 4 | 10.3% |
| λ light chain | 1 | 2.6% |
| ISS, n (%) | ||
| I | 23 | 59.0% |
| II | 10 | 25.6% |
| III | 6 | 15.4% |
| R-ISS, n (%) | ||
| I | 21 | 53.8% |
| II | 14 | 35.9% |
| III | 4 | 10.3% |
| HRC∗ | 15 | 38.5% |
| Del17p | 1 | 2.6% |
| t(4;14) | 1 | 2.6% |
| t(14;16) | 2 | 5.1% |
| t(14;20) | 2 | 5.1% |
| Gain or amplification of 1q | 14 | 35.9% |
| Prestudy cycle of therapy, n (%) | 21 | 53.8% |
| Follow-up time, median (range), mo | 30.1 | 1.7-45.0 |
| . | N = 39 . | |
|---|---|---|
| Sex, n (%) | ||
| Male | 28 | 71.8% |
| Female | 11 | 28.2% |
| Race, n (%) | ||
| White | 26 | 66.7% |
| Black | 12 | 30.8% |
| Asian | 1 | 2.6% |
| Ethnicity, n (%) | ||
| Hispanic/Latino | 1 | 2.6% |
| Non-Hispanic | 37 | 94.9% |
| Unknown | 1 | 2.6% |
| Age at on study, median (range), y | 62 | 34-78 |
| M-protein isotype, n (%) | ||
| IgGκ | 20 | 51.3% |
| IgGλ | 10 | 25.6% |
| IgAκ | 2 | 5.1% |
| IgAλ | 2 | 5.1% |
| κ light chain | 4 | 10.3% |
| λ light chain | 1 | 2.6% |
| ISS, n (%) | ||
| I | 23 | 59.0% |
| II | 10 | 25.6% |
| III | 6 | 15.4% |
| R-ISS, n (%) | ||
| I | 21 | 53.8% |
| II | 14 | 35.9% |
| III | 4 | 10.3% |
| HRC∗ | 15 | 38.5% |
| Del17p | 1 | 2.6% |
| t(4;14) | 1 | 2.6% |
| t(14;16) | 2 | 5.1% |
| t(14;20) | 2 | 5.1% |
| Gain or amplification of 1q | 14 | 35.9% |
| Prestudy cycle of therapy, n (%) | 21 | 53.8% |
| Follow-up time, median (range), mo | 30.1 | 1.7-45.0 |
Data for N = 39 patients.
ISS, International Staging System; R-ISS, Revised International Staging System; HRC, High Risk Cytogenetics.
∗High risk cytogenetics is defined as del17p, t(4;14), t(14;16), t(14;20), and/or gain or amplification of 1q.